Economic evaluation of reproductive carrier screening for recessive genetic conditions: a systematic review.

Wang, T; Bahrampour, M; Byrnes, J; Scuffham, P; Kirk, E; Downes, M

Economic evaluation of reproductive carrier screening for recessive genetic conditions: a systematic review.

Wang, T Bahrampour, M

Byrnes, J Scuffham, P Kirk, E Downes, M

Permalink

Publisher:: Informa UK Limited
Publication Type:: Journal Article
Citation:: Expert Rev Pharmacoecon Outcomes Res, 2021, pp. 1-10
Issue Date:: 2021-10-26

Closed Access

	Filename	Description	Size
	Bahrampour_Genetic conditions.pdf	Published version	2.63 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Wang, T
dc.contributor.author	Bahrampour, M https://orcid.org/0000-0002-6915-1865
dc.contributor.author	Byrnes, J
dc.contributor.author	Scuffham, P
dc.contributor.author	Kirk, E
dc.contributor.author	Downes, M
dc.date.accessioned	2022-01-17T22:42:18Z
dc.date.available	2022-01-17T22:42:18Z
dc.date.issued	2021-10-26
dc.identifier.citation	Expert Rev Pharmacoecon Outcomes Res, 2021, pp. 1-10
dc.identifier.issn	1473-7167
dc.identifier.issn	1744-8379
dc.identifier.uri	http://hdl.handle.net/10453/153231
dc.description.abstract	INTRODUCTION: Autosomal recessive (AR) and x-linked (XL) conditions are rare but collectively common which impact millions of people globally on morbidity, mortality and costs. Advanced medical technologies allow prospective parents to make informed reproductive decisions to avoid having affected children. Economic evaluations targeting on reproductive carrier screening (RCS) for AR and/or XL conditions have been conducted, but there has not been a systematic review in this area. AREAS COVERED: A systematic search of economic evaluations for RCS was undertaken using the following databases - EMBASE, MEDLINE and SCOPUS. The search strategy was designed to capture full economic evaluations related to RCS since 1990. This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) strategy. The included 23 studies adopted various types of methodologies to conduct economic evaluations. The majority of studies examined a single condition. The various clinical strategies and screened conditions caused the different cost-effectiveness conclusions in the published studies. EXPERT OPINION: Establishing a validated and practical clinical strategy of RCS and investigating the cost-effectiveness of multiple conditions in one economic evaluation are critical for implementing RCS in the future. Further economic evaluations are essential to provide evidence-based practice for decision-makers.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Informa UK Limited
dc.relation.ispartof	Expert Rev Pharmacoecon Outcomes Res
dc.relation.isbasedon	10.1080/14737167.2022.1993063
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1115 Pharmacology and Pharmaceutical Sciences, 1117 Public Health and Health Services, 1402 Applied Economics
dc.subject.classification	Health Policy & Services
dc.title	Economic evaluation of reproductive carrier screening for recessive genetic conditions: a systematic review.
dc.type	Journal Article
utslib.location.activity	England
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
utslib.for	1117 Public Health and Health Services
utslib.for	1402 Applied Economics
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Centre for Health Economics Research and Evaluation
utslib.copyright.status	closed_access	*
dc.date.updated	2022-01-17T22:42:16Z
pubs.publication-status	Published online

Abstract:

INTRODUCTION: Autosomal recessive (AR) and x-linked (XL) conditions are rare but collectively common which impact millions of people globally on morbidity, mortality and costs. Advanced medical technologies allow prospective parents to make informed reproductive decisions to avoid having affected children. Economic evaluations targeting on reproductive carrier screening (RCS) for AR and/or XL conditions have been conducted, but there has not been a systematic review in this area. AREAS COVERED: A systematic search of economic evaluations for RCS was undertaken using the following databases - EMBASE, MEDLINE and SCOPUS. The search strategy was designed to capture full economic evaluations related to RCS since 1990. This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) strategy. The included 23 studies adopted various types of methodologies to conduct economic evaluations. The majority of studies examined a single condition. The various clinical strategies and screened conditions caused the different cost-effectiveness conclusions in the published studies. EXPERT OPINION: Establishing a validated and practical clinical strategy of RCS and investigating the cost-effectiveness of multiple conditions in one economic evaluation are critical for implementing RCS in the future. Further economic evaluations are essential to provide evidence-based practice for decision-makers.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/153231